<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2019-10-09" updated="2019-11-02">
  <drugbank-id primary="true">DB15528</drugbank-id>
  <name>Onasemnogene abeparvovec</name>
  <description>Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene.[L9194] SMA is a rare genetic disease that affects the survival and function of motor neurons, leading to debilitating and often fatal muscle weakness.[A187250] As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms. The use and effectiveness of onasemnogene abeparvovec in patients with advanced SMA, such as those with complete paralysis of the limbs and permanent dependence on ventilators, has not been evaluated. Onasemnogene abeparvovec is the first gene therapy that was approved for this indication in the USA. [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients.&#13;
&#13;
Developed by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion.[L9194] Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA.[A187253]</description>
  <cas-number>1922968-73-7</cas-number>
  <unii>B769I4XPY3</unii>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A187250</ref-id>
        <pubmed-id>29091557</pubmed-id>
        <citation>Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK: Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2;377(18):1713-1722. doi: 10.1056/NEJMoa1706198.</citation>
      </article>
      <article>
        <ref-id>A187253</ref-id>
        <pubmed-id>31270752</pubmed-id>
        <citation>Hoy SM: Onasemnogene Abeparvovec: First Global Approval. Drugs. 2019 Jul;79(11):1255-1262. doi: 10.1007/s40265-019-01162-5.</citation>
      </article>
      <article>
        <ref-id>A187256</ref-id>
        <pubmed-id>19271042</pubmed-id>
        <citation>Hasanzad M, Golkar Z, Kariminejad R, Hadavi V, Almadani N, Afroozan F, Salahshurifar I, Shafeghati Y, Kahrizi K, Najmabadi H: Deletions in the survival motor neuron gene in Iranian patients with spinal muscular atrophy. Ann Acad Med Singapore. 2009 Feb;38(2):139-41.</citation>
      </article>
      <article>
        <ref-id>A187259</ref-id>
        <pubmed-id>29766031</pubmed-id>
        <citation>Wang D, Li S, Gessler DJ, Xie J, Zhong L, Li J, Tran K, Van Vliet K, Ren L, Su Q, He R, Goetzmann JE, Flotte TR, Agbandje-McKenna M, Gao G: A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. Mol Ther Methods Clin Dev. 2018 Mar 16;9:234-246. doi: 10.1016/j.omtm.2018.03.004. eCollection 2018 Jun 15.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L9194</ref-id>
        <title>ZOLGENSMA® (onasemnogene abeparvovec-xioi) FDA Label</title>
        <url>https://www.fda.gov/media/126109/download</url>
      </link>
      <link>
        <ref-id>L9209</ref-id>
        <title>SMN1 gene - Genetics Home Reference - NIH</title>
        <url>https://ghr.nlm.nih.gov/gene/SMN1</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Onasemnogene abeparvovec is indicated for the treatment of pediatric patients less than 2 years of age (neonatal and infant patients) with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.[L9194]</indication>
  <pharmacodynamics>Onasemnogene abeparvovec is a gene therapy that restores the levels of SMN protein in the spinal cord to promote the survival and function of motor neurons. Acute serious liver injury and elevated aminotransferases were observed with the treatment of onasemnogene abeparvovec in clinical trials.[L9194]</pharmacodynamics>
  <mechanism-of-action>Spinal muscular atrophy is a genetic disorder caused by mutations in the SMN gene, which encodes the SMN protein. SMN protein is found ubiquitously but it is highly expressed in the spinal cord where it is responsible for the survival and maintenance of specialized nerve cells called motor neurons.[L9209] SMN1 and SMN2 genes encode the SMN protein but many mutations in the SMN1 gene have been found to cause spinal muscular atrophy,[A187256,L9209] as SMN1 is the primary gene responsible for functional production of SMN protein.[A187250] A common mutation that causes spinal muscular atrophy involves a bi-allelic deletion of exon 7 in the SMN1 gene.[A187256] The number of copies of the SMN2 gene varies among individuals: while higher number of SMN2 gene copies may protect against SMN protein deficiency caused by SMN1 gene mutations,[L9209] it is generally proposed that the bi-allelic mutation in the SMN1 gene cannot be compensated by the SMN2 gene.[A187256] The mutation results in insufficient SMN protein expression and inefficient assembly of the machinery needed to process pre-mRNA for motor neuron development and survival. Spinal muscular atrophy involves a progressive degeneration and loss of lower motor neurons, leading to muscle weakness and atrophy.[A187250,L9194]&#13;
&#13;
Onasemnogene abeparvovec is gene therapy that consists of a recombinant self-complementary adeno-associated virus serotype 9 (AAV9) as a gene delivery vector, which contains a transgene encoding the human survival motor neuron (SMN) protein.[A187250,L9194] AAV9 is commonly used in gene therapy applications because it is capable of crossing the blood-brain barrier and transducing neurons in the CNS.[A187259] After administration, this viral vector is shed and a copy of the gene encoding the human SMN protein is delivered, leading to cell transduction and expression of the SMN protein.[L9194]</mechanism-of-action>
  <toxicity>The LD&lt;sub&gt;50&lt;/sub&gt; and information on overdose have not been evaluated with onasemnogene abeparvovec. In mice toxicology studies, dose-dependent cardiac and hepatic toxicities were observed following intravenous administration. Cardiac toxicity was characterized by mononuclear cell inflammation accompanied by edema, slight to mild fibrosis, and scattered myocardial cell degeneration/regeneration, as well as atrial thrombosis and dilation. Hepatotoxicity was characterized by hepatocellular hypertrophy, Kupffer cell activation, perinuclear vacuolation, and scattered hepatocellular necrosis.[L9194]</toxicity>
  <metabolism>There is limited pharmacokinetic information on onasemnogene abeparvovec. The viral vector and the survival motor neuron (SMN) protein are expected to undergo normal nonspecific cellular degradation.</metabolism>
  <absorption>There is limited pharmacokinetic information on onasemnogene abeparvovec.</absorption>
  <half-life>There is limited pharmacokinetic information on onasemnogene abeparvovec.</half-life>
  <protein-binding>There is limited pharmacokinetic information on onasemnogene abeparvovec.</protein-binding>
  <route-of-elimination>There is limited pharmacokinetic information on onasemnogene abeparvovec.</route-of-elimination>
  <volume-of-distribution>There is limited pharmacokinetic information on onasemnogene abeparvovec. When biodistribution was evaluated in autopsy studies, the highest levels of vector DNA were found in the liver. Vector DNA was also detected in the spleen, heart, pancreas, inguinal lymph node, skeletal muscles, peripheral nerves, kidney, lung, intestines, spinal cord, brain, and thymus.[L9194]</volume-of-distribution>
  <clearance>There is limited pharmacokinetic information on onasemnogene abeparvovec.</clearance>
  <salts/>
  <synonyms>
    <synonym language="english" coder="inn/usan">Onasemnogene abeparvovec</synonym>
    <synonym language="english" coder="">onasemnogene abeparvovec-xioi</synonym>
  </synonyms>
  <products>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-125</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-125</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-128</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-128</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-129</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-131</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-131</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-132</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-133</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-133</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-135</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-137</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-137</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-138</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-139</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-139</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zolgensma</name>
      <labeller>AveXis, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71894-141</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec + Onasemnogene abeparvovec</ingredients>
    </mixture>
    <mixture>
      <name>Zolgensma</name>
      <ingredients>Onasemnogene abeparvovec</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Biological Products</category>
      <mesh-id>D001688</mesh-id>
    </category>
    <category>
      <category>Genetic Therapy</category>
      <mesh-id>D015316</mesh-id>
    </category>
    <category>
      <category>Hepatotoxic Agents</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form/>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB12978</drugbank-id>
      <name>Pexidartinib</name>
      <description>Onasemnogene abeparvovec may increase the hepatotoxic activities of Pexidartinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10317</drugbank-id>
      <name>Rubella virus vaccine</name>
      <description>The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Onasemnogene abeparvovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10318</drugbank-id>
      <name>Varicella Zoster Vaccine (Live/attenuated)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Onasemnogene abeparvovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10343</drugbank-id>
      <name>Bacillus calmette-guerin substrain tice live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Onasemnogene abeparvovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10804</drugbank-id>
      <name>Bacillus calmette-guerin substrain connaught live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Onasemnogene abeparvovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10805</drugbank-id>
      <name>Yellow Fever Vaccine</name>
      <description>The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Onasemnogene abeparvovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11003</drugbank-id>
      <name>Anthrax vaccine</name>
      <description>The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Onasemnogene abeparvovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11050</drugbank-id>
      <name>Typhoid Vaccine Live</name>
      <description>The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Onasemnogene abeparvovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12386</drugbank-id>
      <name>Bacillus calmette-guerin substrain danish 1331 live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Onasemnogene abeparvovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Onasemnogene abeparvovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14409</drugbank-id>
      <name>Human adenovirus e serotype 4 strain cl-68578 antigen</name>
      <description>The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Onasemnogene abeparvovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14443</drugbank-id>
      <name>Vibrio cholerae CVD 103-HgR strain live antigen</name>
      <description>The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Onasemnogene abeparvovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14685</drugbank-id>
      <name>Adenovirus type 7 vaccine live</name>
      <description>The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Onasemnogene abeparvovec.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D11559</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Onasemnogene_abeparvovec</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>